James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options
2018 ASCO-SITC Clinical Immuno-Oncology SymposiumJames L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.
Related Videos
Jeffrey M. Lemons, MD, on Solid Tumors: Safety Data on SBRT and Immunotherapy
Jeffrey M. Lemons, MD, of the University of Chicago, discusses early safety and efficacy findings from a small study on pembrolizumab and multiorgan-site ablative stereotactic body...
Linda Mileshkin, MBBS, on Solid Tumors: Early Treatment Study Results
Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor ...
Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Immunotherapy Update
Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.
Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments
Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging...
Aaron Goodman, MD, on Immune Checkpoint Blockade: Clinical Implications
Aaron Goodman, MD, of the University of California, San Diego School of Medicine, discusses an analysis of more than 100,000 patients with cancer for CD274 (PD-L1) amplification an...
